Columbia agrees to pay $200 million in deal with Trump administration to restore federal funding
Under the terms of the agreement, Columbia agreed to pay the government a $200 million settlement over three years and an additional $21 million to settle US Equal Employment Opportunity Commission investigations.
In exchange, the university said in its statement, 'a vast majority of the federal grants which were terminated or paused in March 2025—will be reinstated and Columbia's access to billions of dollars in current and future grants will be restored.'
This is a developing story and will be updated.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
What Makes Eli Lilly and Company (LLY) a Lucrative Investment?
Baron Funds, an investment management company, released its 'Baron Health Care Fund' second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund declined 5.06% (Institutional Shares) in the quarter, against a challenging backdrop for the broader Health Care sector, compared to a 6.19% decline for the Russell 3000 Health Care Index (benchmark) and a 10.99% gain for the Russell 3000 Index (the Index). In addition, please check the fund's top five holdings to know its best picks in 2025. In its second-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as Eli Lilly and Company (NYSE:LLY). Eli Lilly and Company (NYSE:LLY) is a pharmaceutical company headquartered in Indianapolis, Indiana. The one-month return of Eli Lilly and Company (NYSE:LLY) was -2.64%, and its shares lost 5.52% of their value over the last 52 weeks. On July 30, 2025, Eli Lilly and Company (NYSE:LLY) stock closed at $760.08 per share, with a market capitalization of $682.351 billion. Baron Health Care Fund stated the following regarding Eli Lilly and Company (NYSE:LLY) in its second quarter 2025 investor letter: "We added to our position in Eli Lilly and Company (NYSE:LLY), a global pharmaceutical company best known for developing and selling GLP-1 medications for diabetes and obesity. The most recent generation of GLP-1 drugs (brand names Mounjaro and Zepbound) not only offer superb blood sugar control for diabetics, but also can drive 20% or greater weight loss and likely improve cardiovascular outcomes in both diabetic and non-diabetic obese patients. We think these drugs will become the standard of care for both diabetes and obesity, and will become a $150 billion category. We see Lilly as the leader in the space, setting a high efficacy bar with their GLP-1s on the market and continuing to innovate and develop next-generation medications that are more effective and more convenient. We are excited about once-daily oral orforglipron, which recently showed Phase 3 data in type 2 diabetes that rivaled Novo Nordisk's injectable Ozempic. We expect Phase 3 orforglipron in obesity this summer to also be competitive with Novo Nordisk's injectable Wegovy. Beyond orforglipron, Lilly is also studying a high efficacy injectable (retatrutide) in Phase 3, an amylin hormone analogue (eloralintide) that can be combined with Zepbound in Phase 2, and a muscle preserving drug bimagrumab (which can also be combined with Zepbound) in Phase 2. We continue to think this market is in the early innings of uptake, we think the adoption of GLP-1s will drive Lilly to triple its total revenues by 2030, and we think Lilly has the pipeline portfolio of drugs to sustain its leadership position." Eli Lilly and Company (NYSE:LLY) is in 21st position on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 119 hedge fund portfolios held Eli Lilly and Company (NYSE:LLY) at the end of the first quarter, which was 115 in the previous quarter. Eli Lilly and Company (NYSE:LLY) reported strong results in first quarter of 2025, with revenue increasing 45% compared to Q1 2024. While we acknowledge the potential of Eli Lilly and Company (NYSE:LLY) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Eli Lilly and Company (NYSE:LLY) and shared the list of stocks Jim Cramer recently discussed. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 minutes ago
- Yahoo
Excellent Execution Drove IDEXX Laboratories (IDXX) Shares Amid Macro Challenges
Baron Funds, an investment management company, released its 'Baron Health Care Fund' second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund declined 5.06% (Institutional Shares) in the quarter, against a challenging backdrop for the broader Health Care sector, compared to a 6.19% decline for the Russell 3000 Health Care Index (benchmark) and a 10.99% gain for the Russell 3000 Index (the Index). In addition, please check the fund's top five holdings to know its best picks in 2025. In its second-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as IDEXX Laboratories, Inc. (NASDAQ:IDXX). IDEXX Laboratories, Inc. (NASDAQ:IDXX) develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets. The one-month return of IDEXX Laboratories, Inc. (NASDAQ:IDXX) was 4.58%, and its shares gained 22.08% of their value over the last 52 weeks. On July 30, 2025, IDEXX Laboratories, Inc. (NASDAQ:IDXX) stock closed at $572.09 per share, with a market capitalization of $46.009 billion. Baron Health Care Fund stated the following regarding IDEXX Laboratories, Inc. (NASDAQ:IDXX) in its second quarter 2025 investor letter: "Shares of veterinary diagnostics leader IDEXX Laboratories, Inc. (NASDAQ:IDXX) contributed to performance for the quarter after reporting better than-expected financial results. Foot traffic to veterinary clinics in the U.S. remains under pressure, which has continued to hamper aggregate revenue growth. Despite macroeconomic challenges, IDEXX's excellent execution has enabled the company to maintain strong performance. We believe competitive trends are outstanding, and we expect new proprietary innovations and field sales force expansion to be meaningful contributors to growth in 2025. We see increasing evidence that long-term secular trends around pet ownership and pet care spending have structurally accelerated, which should help support IDEXX's long-term growth rate." A veterinarian in a veterinary clinic examining a companion animal. IDEXX Laboratories, Inc. (NASDAQ:IDXX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 51 hedge fund portfolios held IDEXX Laboratories, Inc. (NASDAQ:IDXX) at the end of the first quarter, which was 58 in the previous quarter. In the first quarter of 2025, IDEXX Laboratories, Inc. (NASDAQ:IDXX) reported organic revenue growth of 5% driven by 4.5% organic revenue gains in the CAG business, 7% organic growth in water, and 4% organic growth in LPD. While we acknowledge the potential of IDEXX Laboratories, Inc. (NASDAQ:IDXX) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered IDEXX Laboratories, Inc. (NASDAQ:IDXX) and shared the list of best stocks to buy according to Brasada Capital Management. In Q2 2025, IDEXX Laboratories, Inc. (NASDAQ:IDXX) contributed to Conestoga Capital Advisors' performance. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 minutes ago
- Yahoo
'It Gets Worse': The White House Just Weighed In On All The American Eagle Backlash, And It's Not A Good Look For Sydney Sweeney
As you've probably seen, Sydney Sweeney and American Eagle have been copping a lot of backlash over their new denim ads. The new jeans campaign has been hit with complaints about everything from Sydney's hypersexualization to the tone of her voice. However, it's fair to say that the biggest talking point has been around the perceived racial undertones and links to eugenics. For context, the tagline of the campaign is 'Sydney Sweeney has great jeans,' and, as is explicitly pointed out, the whole thing is a play on Sydney's 'great genes.' Some people have taken issue with the glorification of Sydney's genetics as a blonde-haired, blue-eyed, white woman, accusing AE of promoting eugenics and 'white supremacy.' One of the clips that received the most backlash centers on Sydney saying: 'Genes are passed down from parents to offspring, often determining traits like hair color, personality, and even eye color. My jeans are blue.' This video has seemingly been pulled from AE's social pages. Related: Especially in the current political climate, being accused of promoting whiteness is not a great look for the brand, nor for Sydney, who has previously had to address 'misinterpretations' about her and her family's political stance after people on her Instagram page were seen wearing MAGA-style hats. It's worth mentioning that Sydney has remained publicly apolitical amid conversations about her family's political beliefs. Now, as the AE discourse continues to develop online, the government has weighed in on the conversation. On July 29, White House communications manager Steven Cheung took to X to share a screenshot of an MSNBC headline suggesting that the AE ad is indicative of an 'unbridled cultural shift toward whiteness.' Slamming 'dense liberal thinking,' Cheung called the reaction: 'Cancel culture run amok.' 'This warped, moronic, and dense liberal thinking is a big reason why Americans voted the way they did in 2024,' he wrote. 'They're tired of this bullshit.' As you can imagine, the White House's response has only fueled conversations about Sydney and the divisive campaign. The latest reactions online are pretty intense, with people highlighting that it hasn't exactly made the situation any better, and it's also not a good look for Sydney to have the Trump administration aligning itself with her. Related: Related: Meanwhile, others expressed confusion and disbelief that the White House even took the time to address the discourse, asking, 'do you not have a country to run?' Related: Neither Sydney nor AE has publicly addressed the backlash, but has this made things worse? LMK your thoughts in the comments. More on this Doja Cat Just Mocked Sydney Sweeney's American Eagle Ad Campaign, And You Need To See ThisEllen Durney · July 29, 2025 Sydney Sweeney's New Jeans Campaign Is Getting Backlash For TaglineNatasha Jokic · July 28, 2025 Sydney Sweeney Said The People Who Wore Those MAGA-Style Caps To Her Mom's Viral Birthday Party Thought It'd Be 'Funny' As She Addressed Fans' 'Misinterpretations'Leyla Mohammed · Aug. 10, 2023 Also in Celebrity: Also in Celebrity: Also in Celebrity: Solve the daily Crossword
